Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
April 15, 2026
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
June 7, 2021
Related Post
-
-
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 14, 2026
-
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
April 13, 2026
-
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
April 13, 2026